logo
Even low doses of CBD may cause harm to the liver, FDA study finds

Even low doses of CBD may cause harm to the liver, FDA study finds

Yahoo3 days ago
A new clinical trial suggests there are still ongoing questions about the safety of even low doses of cannabidiol, even as CBD capsules, gummies, edibles, oils and lotions have become increasingly omnipresent in the United States in recent years.
Scientists from the Food and Drug Administration's Division of Applied Regulatory Science carried out a randomized double-blind placebo-controlled trial last year to assess how low-dose CBD affects liver function in a group of healthy middle-aged men and women.
Over the course of four weeks, 201 volunteers received either 5 mg per kilogram of body weight (approximately 2.3 mg per pound or the equivalent of 350 mg for a 154-pound individual) of oral CBD, or a placebo. The goal was to give them a typical amount that might be used by consumers. Participants also underwent weekly laboratory assessments.
While the vast majority of people in the trial were unaffected, 5% showed greatly elevated levels of the liver enzyme aminotransferase, a known marker of liver cell damage or inflammation, according to the study published Monday in JAMA Internal Medicine. Women appeared to be more vulnerable than men. The liver enzyme returned to normal within one or two weeks of stopping CBD.
Seven participants withdrew from the trial because they were showing clinical signs of potential drug-induced liver injury.
The FDA didn't respond immediately to a request for comment.
'This is a significant finding, as it suggests that CBD itself, even in the absence of other drugs, may pose a risk to liver health,' says Amir Englund, a researcher at King's College London who studies cannabinoid psychopharmacology, and was not involved in the new trial. 'The results have important implications for individuals using over-the-counter CBD supplements. Many may be unaware of the potential for liver injury and assume that CBD is entirely benign.'
Between 2014 and 2022, CBD product sales in the U.S. increased from $108 million to $1.9 billion, after a landmark bill passed by the Trump administration in 2018 enabled the unrestricted sale of cannabis products containing less than 0.3% THC, the psychoactive element which gets users high.
According to various surveys in recent years, the majority of people in the U.S. have now heard of CBD, and around 20% have reported using CBD products in the past 12 months.
While CBD products have become a popular way to self-medicate for conditions including pain, anxiety, insomnia and depression, especially among older adults, there's been little evidence on how well they work or guidance on how to use the products safely.
Signs of liver injury include abdominal discomfort, jaundice or yellowing of the skin and eyes, and fatigue.
However, research has shown that drug-induced liver injuries don't always become immediately apparent. In the FDA trial, only one of the participants with elevated liver enzymes noticed any symptoms within four weeks. The authors suggested that users may not realize that they are incurring harm and that doctors should ask about regular CBD use as part of routine medical screening.
'This was an important observation from the study,' said Paul Watkins, professor of pharmacy at the University of North Carolina at Chapel Hill. 'When doctors get liver chemistry results back and they're out of whack, they should be aware to ask, 'Were you taking CBD?' Because a lot of people are.'
The new trial is not the first study to suggest potential health risks relating to cannabidiol and its effects on the liver. Such concerns were initially described following an FDA review of clinical trial data on CBD-based prescription drugs for childhood epilepsy, with raised liver enzymes being observed in 14% of participants.
'In clinical trials involving epilepsy patients, elevated levels of liver enzymes were among the leading causes of withdrawal from the trials due to serious adverse events,' Englund said 'However, those participants were concurrently taking other anti-epileptic medications, which could have contributed to the observed liver effects.'
Watkins was subsequently involved in research investigating why CBD can affect liver cells, and he said that certain doses seem to have an effect similar to acetaminophen, or paracetamol.
'It's interesting because it's also been shown that healthy adults, when they get recurrent therapeutic doses of paracetamol, also have these liver chemistry abnormalities,' Watkins said.
In the U.S., acetaminophen, when taken in excess, is among the most common causes of drug-induced liver injury, also called toxic hepatitis.
In the last few years, research studies have shown that people most at risk of liver injury are those taking very high oral doses of CBD, exceeding 1000 mg per day. There have still been reports of drug-induced liver injuries in some healthy individuals taking moderate doses of anywhere between 300 mg and 1000 mg per day.
Relatively little is known about why some people are more susceptible than others, but it is thought that genetic factors may play a role. According to Englund, CBD can inhibit certain enzymes in the liver which are needed for metabolizing medications.
In the new FDA trial, the majority of participants who experienced the most serious liver problems also developed signs of an immune condition called eosinophilia, which is when the body produces an excess of a type of white blood cell called eosinophils.
The new results emphasize the importance of tracking liver safety as a potential, unintended adverse effect, Englund said.
'Given the growing interest in CBD as a potential treatment for conditions such as psychosis and cannabis use disorder, these findings underscore the importance of monitoring liver enzyme levels in future clinical trials,' he said.
Overall, Watkins — who co-chairs the Drug-Induced Liver Injury Network, a research group backed by the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health — still believes CBD is relatively safe.
While over-the-counter supplements are becoming a growing potential cause of significant liver injuries, CBD has yet to be flagged as a source of concern, he said.
'Overall, the liver is very good at adjusting to sources of drug stress [indicated by elevated enzymes],' Watkins said, noting the network hasn't detected a case of serious liver injury attributed to CBD. "There could be people out there whose liver doesn't adjust very well, and as companies compete for market share, you might start getting more potent CBD which could push people into the ranges where they're getting into trouble, but the data we've got suggests it's very safe.'
This article was originally published on NBCNews.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Actress reveals how cancer test that saved her life led to surprising family discovery
Actress reveals how cancer test that saved her life led to surprising family discovery

Fox News

time19 minutes ago

  • Fox News

Actress reveals how cancer test that saved her life led to surprising family discovery

Olivia Munn, who previously claimed that a breast cancer risk assessment test saved her life, announced on social media this week that it also saved her mother's life. "My mother was diagnosed with breast cancer," the actress, 45, wrote in her caption. "You may know that when I talk about my own battle with cancer, I bring up the Lifetime Risk Assessment test that saved my life. I never would've predicted it would save my mom's life as well." While there are several risk assessment tools available to patients and physicians, the breast cancer risk assessment tool (BCRAT) is one of the most common, Fox News Digital previously reported. The BCRAT is based on a statistical model known as the Gail Model. It's named after Dr. Mitchell Gail, an NIH distinguished investigator at the National Cancer Institute, according to a National Cancer Institute (NCI) spokesperson. The five-minute test helps predict a woman's risk of developing invasive breast cancer within the next five years, and up to 90 years of age, according to the NCI. Just one year ago, Munn credited the test with prompting her to get a biopsy – even after mammograms and genetic testing came back negative. The biopsy showed she had Luminal B cancer in both breasts. Luminal B is an aggressive, fast-moving cancer. The BCRAT calculates a woman's "absolute breast cancer risk." On its website, the organization defines this as the "chance or probability of developing invasive breast cancer in a defined age interval." The risk calculator considers factors including age, race, medical history and reproductive history. It also looks at the family history of breast cancer among relatives like mothers, sisters and daughters. Once the information is calculated, users are provided with a score. Fox News Digital previously reported that a five-year risk score of 1.67% or more is considered high-risk. A healthcare provider may recommend certain medications to decrease the chances of developing cancer, according to Cleveland Clinic's website. For more Health articles, visit Dr. Nicole Saphier, M.D., board-certified breast imaging radiologist and associate professor at Memorial Sloan Kettering Cancer Center in New York City, recommends individual risk assessments to her referring clinicians and patients. "Olivia Munn's doctor may have saved her life by doing so," Saphier previously said in a statement to Fox News Digital when news of Munn's diagnosis first broke in 2024. "While a standard mammogram is sufficient for nearly half of all women, many others will benefit from adding an ultrasound or MRI based on breast density and various other factors that may make someone [a] higher risk [candidate]." Less than 5% of all women diagnosed with breast cancer will have cancer in the contralateral (opposite) breast, according to Saphier. "Olivia Munn was one of those rare cases," she said.

GSK begins shipping influenza vaccine doses for the 2025-26 flu season
GSK begins shipping influenza vaccine doses for the 2025-26 flu season

Business Wire

time29 minutes ago

  • Business Wire

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccination is the first and most important action recommended to reduce the risk of flu and its potentially serious outcomes. Ideally, vaccination should occur by the end of October, but people can continue to get vaccinated as long as the flu poses a threat. 1 CDC recommends an annual flu vaccination for anyone aged six months or older who does not have contraindications. 1,2 CDC estimates that from October 1, 2024, through May 17, 2025, there were 47 – 82 million flu illnesses, 610,000 – 1.3 million flu hospitalizations and 27,000 – 130,000 flu deaths. 3 The 2024-25 flu season was the first season since 2017-18 that the CDC classified as high severity, and preliminary CDC estimates indicate that it was the worst flu season (based on flu illnesses, hospitalizations and deaths) the US has seen in the last 15 years. 4,5 For egg-based influenza vaccines for the 2025-26 flu season in the Northern Hemisphere, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended including an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Croatia/10136RV/2023 (H3N2)-like virus and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus. 6 About Influenza The flu is a contagious respiratory illness caused by influenza viruses that infect the nose, throat and sometimes the lungs. It can cause mild-to-severe illness and at times can lead to death. 7 Anyone, including healthy people, can get the flu, however, it can be more serious for children younger than five, adults 65 years and older, people with a body mass index (BMI) of 40 kg/m 2 or higher, pregnant women and people with pre-existing chronic health conditions, such as asthma, diabetes and heart disease. 7 For more information about the flu, visit Indication for FLUARIX and FLULAVAL FLUARIX and FLULAVAL are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B virus contained in the vaccines. FLUARIX and FLULAVAL are approved for use in persons aged 6 months and older. Important Safety Information for FLUARIX and FLULAVAL Do not administer FLUARIX or FLULAVAL to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX or FLULAVAL should be based on careful consideration of the potential benefits and risks. Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX and FLULAVAL. Procedures should be in place to avoid injury from fainting. Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUARIX and FLULAVAL. If FLUARIX or FLULAVAL is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons. The most common solicited local adverse reactions with FLUARIX in adults were pain and redness, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 5 through 17 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were muscle aches, fatigue, and headache. In children aged 3 through 4 years, the most common solicited local adverse reactions were pain, redness, and swelling, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children aged 6 through 35 months who received FLUARIX QUADRIVALENT, the most common solicited local adverse reactions were pain and redness, and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. The most common solicited local adverse reactions with FLULAVAL in adults were pain, redness, and swelling, and the most common solicited systemic adverse reactions were fatigue, headache, and muscle aches/arthralgia. In children aged 3 through 17 years, the most common solicited local adverse reaction was pain. In children aged 3 through 4 years, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children aged 5 through 17 years, the most common solicited systemic adverse reactions were muscle aches, headache, and fatigue. In children aged 6 through 35 months who received FLULAVAL QUADRIVALENT, the most common solicited local adverse reaction was pain, and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. Vaccination with FLUARIX or FLULAVAL may not result in protection of all vaccine recipients. Please see full Prescribing Information for FLUARIX and for FLULAVAL. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in GSK's Annual Report on Form 20-F for 2024. Registered in England & Wales: No. 3888792 References

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store